10-Q quarterly report · filed Nov 5, 2026

TransMedics Group, Inc. (TMDX) Q3 2026 10-Q Quarterly Report

Short answer

TransMedics Group, Inc. (TMDX) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $203M (up 41.1% year over year) with net income of $17M.

Q3 2026 key financials · XBRL

Revenue
$203M
+41.1% YoY · +6.9% QoQ
Net income
$17M
−29.8% YoY · +16.3% QoQ
Operating margin
13.9%
Gross margin
58.5%
EPS (diluted)
$0.47
−28.8% YoY · +14.6% QoQ

Source: XBRL data from the TransMedics Group, Inc. (TMDX) Q3 2026 10-Q on SEC EDGAR. USD.

TransMedics Group, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $203.0M, up $59.2M YoY from $143.8M
  • Gross margin 58% vs 59% YoY, product margin 79% vs 79%
  • OCS Liver strongest, $150.2M vs $107.9M; OCS Lung weakest, $3.1M vs $3.7M
  • Cash $493.0M; nine-month operating cash flow $77.8M vs $158.3M
  • Outlook: revenue growth from NOP and international expansion, with tariff, supply-chain and reimbursement risks

Risk Factors

  • No material changes to risk factors since the 2025 Form 10-K
  • Carried-forward business risks remain detailed in the 2025 Form 10-K
  • No new regulatory, legal, operational, market, or financial risks identified

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other TransMedics Group, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.